annual meeting program - American Society of Clinical Oncology

Monday, June 7, 2010
Brd. 50G A pilot study of sorafenib examining biomarkers in refractory or relapsed
T-cell lymphoma patients. (Abstract #TPS300)
F. Lansigan, M. Komarovskaya, S. Seropian, D. Cooper, F. M. Foss
Brd. 50H Targeting the epigenome: A phase I/II study of vorinostat (SAHA), cladribine
(2-CdA), and rituximab in relapsed B-cell malignancies. (Abstract #TPS301)
S. E. Spurgeon, C. Y. Okada, J. Huang, J. Phillips, E. E. Epner
Brd. 51A A phase II trial of fludarabine and cyclophosphamide followed by thalidomide
for angioimmunoblastic lymphoma. (Abstract #TPS302)
C. Rudin, R. J. Johnson, B. Pottinger, P. Smith, O. A. Adedayo
Brd. 51B A randomized, open-label, multicenter phase II study of bortezomib with
fludarabine in comparison to rituximab with fludarabine in follicular
lymphoma subjects previously treated with rituximab. (Abstract #TPS303)
P. Theocharous, O. Shpilberg, Y. A. Elsayed
Brd. 51C RCHOPB: Feasibility study of RCHOP plus bevacizumab (B) in patients (pts)
with diffuse large B-cell lymphoma (DLBCL). (Abstract #TPS304)
E. A. Hawkes, I. Chau, K. Thomas, J. R. Oates, J. Webb, C. Costello, P. W.
Johnson, D. Cunningham
Brd. 51D Phase II safety and efficacy study of CT-011, a humanized anti-PD-1
monoclonal antibody, in combination with rituximab in patients with relapsed
follicular lymphoma. (Abstract #TPS305)
J. R. Westin, F. Chu, M. Foglietta, R. Rotem-Yehudar, S. S. Neelapu
Brd. 51E A randomized phase II trial of maintenance versus consolidation bortezomib
therapy following aggressive chemo-immunotherapy and autologous stem
cell transplant for previously untreated mantle cell lymphoma. (Abstract
#TPS306)
L. D. Kaplan, S. Jung, J. L. Johnson, C. A. Linker, J. C. Byrd, W. Stock, E. D. Hsi,
B. D. Cheson
Brd. 51F Phase II multisite study to evaluate efficacy and safety of single weekly
administration of bortezomib (BZ) and dexmethasone (dex) in newly
diagnosed multiple myeloma (NDMM) patients (pts). (Abstract #TPS307)
N. C. Munshi, S. Lee, G. D. Roodman, C. Behler, S. Kambhampati, M. G. Rose,
M. T. Brophy, A. Houranieh, D. Esseltine, A. Lichtenstein
Brd. 51G PANORAMA 2: A phase II study of panobinostat (LBH589) in combination
with bortezomib (BTZ) and dexamethasone (DEX) in patients with relapsed
and BTZ-refractory multiple myeloma (MM). (Abstract #TPS308)
M. Alsina, S. Lonial, D. M. Weber, S. E. Coutre, B. P. Kang, T. Glynos, G. Warsi,
S. M. Snodgrass, P. G. Richardson
Melanoma/Skin Cancers
Brd. 51H A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1
(GRM1) signaling, in metastatic melanoma. (Abstract #TPS309)
J. M. Mehnert, J. H. Lee, J. Shirk, D. Bhavsar, O. Anosike, J. L. Chan, W. Shih, S.
Chen, J. S. Goydos
Brd. 52A Treatment of melanoma with wild-type p53 (wtp53) and detectable S100B
using pentamidine: A phase II trial with correlative biomarker endpoints.
(Abstract #TPS310)
J. M. Mehnert, P. F. Hausner, M. Tan, D. Weber, E. A. Sausville
Brd. 52B Low-dose temozolomide modulation of peripheral blood regulatory T cells
before dendritic cell-based vaccination in metastatic melanoma: Phase I/II
study. (Abstract #TPS311)
L. Ridolfi, L. Fiammenghi, M. Petrini, A. Granato, V. Ancarani, E. Pancisi, M.
Guidoboni, A. Riccobon, P. A. Ascierto, R. Ridolfi
Brd. 52C A phase II trial of dasatinib in patients with unresectable locally advanced or
stage IV mucosal, acral, and solar melanomas: An Eastern Cooperative
Oncology Group study (E2607). (Abstract #TPS312)
K. Kalinsky, S. J. Lee, D. P. Lawrence, J. M. Kirkwood
331
MONDAY